Navigation Links
Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
Date:5/22/2012

SAN FRANCISCO, May 22, 2012 /PRNewswire/ -- Boehringer Ingelheim announced today results from a Phase II study evaluating the investigational compound tiotropium delivered once-daily via the Respimat® Inhaler in adolescents with symptomatic, moderate persistent asthma. The data were presented at the 2012 Annual Meeting of the American Thoracic Society (ATS 2012). Boehringer Ingelheim announced that a comprehensive confirmatory Phase III trial program named UniTinA-asthma™ is ongoing to fully evaluate the potential of the long-acting bronchodilator in the treatment of asthma in pediatric, adolescent and adult patients. 

The results are from a Phase II, 4-week, randomized, double-blind, placebo-controlled, incomplete cross-over study. This dose-ranging study evaluated 105 patients 12 to 17 years of age with moderate, persistent asthma on medium dose inhaled corticosteroids (ICS) with or without long-acting beta-agonist (LABA) or leukotriene receptor antagonists (LTRA). 

With all dosages of tiotropium administered once daily, lung function was greater as evaluated by peak FEV1(0-3h) (1.25 microgram = 0.566 L; 2.5 microgram = 0.546 L; 5 microgram = 0.602 L), 1.25FEV1AUC(0-3h)  (1.25 microgram = 0.455 L; 2.5 microgram = 0.434 L; 5 microgram = 0.497 L) and trough FEV1 (1.25 microgram = 0.384 L; 2.5 microgram = 0.353 L; 5 microgram = 0.442 L) compared to placebo (0.489 L, 0.363 L, 0.292 L, respectively). A statistically significant increase in lung function was observed with 5 microgram tiotropium administered once daily (peak FEV1(0-3h)  = 0.113 L, p = 0.004; FEV1AUC(0-3h) = 0.133 L, p<0.001;  trough FEV1 = 0.151 L, p<0.001). The 5 microgram dose was chosen for further studies of tiotropium in this patient population.

"Despite substantial advancements in the treatment of asthma and a wide range of available therapeutic optio
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
2. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
3. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
4. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
5. Phase 2b Study of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Shows Undetectable Virus in HCV Genotype-1 Patients 12 Weeks After Treatment Ended (SVR12)
6. Boehringer Ingelheim and Lillys new oral type 2 diabetes treatment for adults, Jentadueto™ (linagliptin/metformin hydrochloride) tablets, now available in U.S. pharmacies
7. Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal Antibodies
8. CompleGen Announces Successful Delivery of Its XenoGene™ Technology to Boehringer Ingelheim for Drug Discovery Under a Non-Exclusive Agreement.
9. AbGenomics International, Inc. Regains Global Rights to AbGn-168H from Boehringer Ingelheim
10. Boehringer Ingelheim Invests More Than $350 Million in 2011 U.S. Expansion Projects
11. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... -- Impax Laboratories, Inc. (NASDAQ: IPXL ) announced today ... financial results on Monday, August 10, 2015, prior to ... will host a conference call and live webcast with ... August 10, 2015. The financial results and ... section of the Company,s Web site at http://investors.impaxlabs.com ...
(Date:7/6/2015)... PARIS , July 6, 2015 ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... Japan,s Ministry of Health, ... Confocal Laser Endomicroscopy solution, the AQ-Flex 19 miniprobe. ... Cellvizio AQ -Flex™ 19 miniprobe is comprised of ...
(Date:7/6/2015)... July 6, 2015  Protiviti, a global consulting firm, ... Auditing around the World publication ( www.protiviti.com/iaworld ). ... reported on the evolution of the internal audit profession ... globe as a means to providing senior executives and ... strategic business function. The 2015 edition of ...
Breaking Medicine Technology:Impax to Report Second Quarter 2015 Results on August 10, 2015 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 3New Edition of Internal Auditing Around the World from Protiviti Explores Changes and Trends 2
... Ill., Oct. 8 Hospira, Inc. (NYSE: HSP ... signed a Business Cooperation Agreement with South Korea-based Celltrion, ... business terms of a future distribution agreement for the ... eight biogeneric products that are currently under development by ...
... , SAN DIEGO, Oct. 8 Adnavance Technologies Inc., ... medical applications, announced today that Randy White, Ph.D. chief ... of DNA targets in human clinical samples during company ... on Tuesday, October 13, 2009 at 10:00 a.m. Eastern ...
Cached Medicine Technology:Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs 2Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs 3Adnavance Technologies to Present Initial Data Supporting Direct Detection Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference 2
(Date:7/6/2015)... ... July 06, 2015 , ... ... southern California, has partnered with Woodbridge Walk-In Urgent Care to offer on-site health ... other serious medical conditions. Screenings are affordable and accurate and run about an ...
(Date:7/6/2015)... ... July 06, 2015 , ... With ... has once again teamed up with Family Emergency Shelter Coalition (FESCO) and announced ... self-sufficiency. FESCO was created especially to provide emergency services and support for homeless ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... $400,000 in grant funds to support a three-year effort to reduce rates of ... will be conducted in partnership with the Morehouse School of Medicine’s Prevention Research ...
(Date:7/6/2015)... , ... July 06, 2015 , ... ... Jeffrey R. Carlson finished his 100th case using SpineFrontier’s® PedFuse® REmind® Screws. The ... Hospital in Newport News, VA. The procedure was an L5-S1 posterior lumbar interbody ...
(Date:7/5/2015)... ... July 06, 2015 , ... Security Life Insurance ... announce the next generation of PrimeStar Individual Dental Insurance. Beginning now, enhancements include ... network options—Maximum Allowable Charge (MAC) and usual, customary and reasonable (UCR). , ...
Breaking Medicine News(10 mins):Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 3Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 3Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2
... of the disease was found to have been cut to half ... The study involving about 6,000 patients over six years in many ... among patients given the drugs. // , The drugs ... strokes and heart attacks and consequently deaths. The drugs cost only ...
... many grueling and expensive options to explore for women who ... ,According to an article from the San Francisco Chronicle, ... been through the other options. They usually face multiple problems ... a certain number of eggs, hundreds are lost with each ...
... programme helps people with chronic illness.Researchers at the ... in Carolina, USA, offered 104 patients with chronic ... eight weeks. ,The patients, who suffered from ... gastrointestinal problems, and high blood pressure, reported dramatic ...
... effects on the heart among the young and old.There ... diameter of less than ten micrometres. These can cause ... circulation, especially in people with pre-existing disease. ... University now reveals that the adverse effects of pollution ...
... for a year at a time can keep lungs ... to American researchers. At the University of Ohahio, Dr.Margit ... ,They studied more than 1,000 Finnish participants in ... had quit permanently, those who had quit intermittently, and ...
... vegans that are very low in animal products can be ... in turn strengthen teeth. ,Dr.Ludwig Leibsohn, faculty in ... a prolonged time can be at risk of periodontal disease. ... D, becoming more susceptible to decay."// ,Deficiencies in ...
Cached Medicine News:
Intermittent catheter...
... Focus from Thermo Labsystems was designed specifically ... Advanced features such as the new fast ... on microvolumes help to define this as ... The new interchangeable handle plate offers a ...
Disease diagnosis and treatment reference sourced from Griffith's 5-Minute Clinical Consult. Save time diagnosing and treating more than 1,200 diseases and conditions....
... Flexible Band is a flexible partial ... alternative for surgeons who desire posterior ... Tailor® Annuloplasty Ring, which is designed ... rings, but like the option of ...
Medicine Products: